Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients

doi:10.12998/wjcc.v10.i14.4327

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 14

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4726)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

390

WORD

156

HTML

2795

Tables (1-1)

205

Sum=3546

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

317

Download

863

Sum=1180

May 16, 2022 (publication date) through May 1, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Opinion Review

World J Clin Cases. May 16, 2022; 10(14): 4327-4333
Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4327

Table 1 Summary of originator biologic products of tumor necrosis factor-α inhibitors and biosimilars

Product	Biosimilar	Country/year	Status
Infliximab (Remicade, Janssen)	CT-P13 (Inflectra or Remsima, Celltrion Healthcare)	USA, EU, Japan	Approved
	SB2 (Flixabi or Renflexis)	EU, Korea, Australia, USA	Approved
	PF-06438179 or GP1111 (Zessly)	EU-2019	Approved
	BOW015 (Infimab)	India-2014, USA, Canada, Europe, Thailand	Approved; pending market approval
	CMAB008	China-2020	Under review/submitted
	Baimaibo	China-2019	Under review/submitted
	NI-071	Japan-2019	Ongoing-Phase III trial completed
	STI-002	China-2016	Ongoing-Phase III trial completed
Adalimumab (Humira, AbbVie)	ABP 501 (Amgen)	USA-2016, Europe-2017	Approved
	SB5 (Imraldi)	Europe-2017	Approved
	ZRC-3197 (Exemptia)	India-2014	Approved
	BI 695501	USA-2017	Approved
	GP2017	Europe-2017	Approved
	FKB327 (Huilo)	Europe-2019	Approved
	PF-06410293 (Amsparity/Abrilada)	Europe and USA-2020	Approved
	LBAL (Adalimumab BS MA)	Japan-2021	Approved
	CHS-1420	USA-2021	Ongoing-Phase III trial completed
	ONS-3010	Europe-2018	Ongoing-Phase III trial
	BOW050	Europe-2017	Under review
	MSB11022	Europe-2019	Under review
	M923	-	Discontinued
Golimumab	BOW100	-	Under review
Golimumab	BAT2506	Europe and USA	Ongoing-Phase III trial
Certolizumab	PF688	USA	Under review
Pegol	Xcimzane	-	Ongoing

EU: European Union; USA: United States.

Citation: Najeeb H, Yasmin F, Surani S. Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients. World J Clin Cases 2022; 10(14): 4327-4333
URL: https://www.wjgnet.com/2307-8960/full/v10/i14/4327.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i14.4327